92 related articles for article (PubMed ID: 33951189)
1. Chronic lymphocytic leukemia and the skin: implications for the dermatologist.
Fried LJ; Criscito MC; Stevenson ML; Pomeranz MK
Int J Dermatol; 2022 May; 61(5):519-531. PubMed ID: 33951189
[TBL] [Abstract][Full Text] [Related]
2. Leukemia Cutis in Skin of Color.
Adjei S; Temiz LA; Miller AC; Sadek R; Grush AE; Tyring SK
J Drugs Dermatol; 2023 Jul; 22(7):687-689. PubMed ID: 37410053
[TBL] [Abstract][Full Text] [Related]
3. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL.
Tam C; Pinilla-Ibarz J; Castillo CG; Fenili AC; Huntley K; Karakus V; Mattar M; Miroli MA; Moura C; Pavlovsky M; Piotrowski F; Šimkovič M; Stilgenbauer S
Blood Adv; 2023 Nov; 7(22):6819-6828. PubMed ID: 37722356
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous lesions of the nose.
Sand M; Sand D; Thrandorf C; Paech V; Altmeyer P; Bechara FG
Head Face Med; 2010 Jun; 6():7. PubMed ID: 20525327
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the management of eosinophilic dermatosis of hematological malignancy.
Tan S; Choong DJ; Tan E
Int J Dermatol; 2024 May; ():. PubMed ID: 38727148
[TBL] [Abstract][Full Text] [Related]
6. The cutaneous manifestations of haematological malignancy.
Fogo A; du Vivier A
Clin Med (Lond); 2009 Aug; 9(4):366-70. PubMed ID: 19728516
[No Abstract] [Full Text] [Related]
7. Chronic lymphocytic leukemia skin infiltrates presenting as eyebrow alopecia and erythematous pruritic papules refractory to treatment with topical steroids.
Zhu JL; Goff HW
Clin Case Rep; 2020 Dec; 8(12):2521-2523. PubMed ID: 33363771
[TBL] [Abstract][Full Text] [Related]
8. Numerous, disseminated, purplish skin nodules in a patient with chronic lymphocytic leukemia.
Sławińska M; Sokołowska-Wojdyło M; Hlebowicz M; Biernat W; Nowicki RJ; Sobjanek M
Pol Arch Intern Med; 2021 Jan; 131(1):81-82. PubMed ID: 33306290
[No Abstract] [Full Text] [Related]
9. Dermatologic manifestations of hematologic disorders.
King HL; Benedetti GB; Keller JJ; DeLoughery TG; Shatzel JJ; Martens KL
Ann Hematol; 2024 Apr; ():. PubMed ID: 38662204
[TBL] [Abstract][Full Text] [Related]
10. An Unusual Presentation of Chronic Lymphocytic Leukaemia.
Paul K; Paul G; Kazal HL; Bairwa NK
J Clin Diagn Res; 2015 Aug; 9(8):OJ01. PubMed ID: 26435991
[No Abstract] [Full Text] [Related]
11. A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States.
Ruan GJ; Smith CJ; Day C; Harmsen WS; Zblewski DL; Alkhateeb H; Begna K; Al-Kali A; Litzow MR; Hogan W; Gangat N; Patnaik MS; Pardanani A; Tefferi A; Go RS; Shah MV
Am J Hematol; 2020 Oct; 95(10):E257-E260. PubMed ID: 32533865
[No Abstract] [Full Text] [Related]
12. Clinical Outcomes in Patients with Multi-Hit
Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
[TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
[TBL] [Abstract][Full Text] [Related]
14. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
Cherng HJ; Jammal N; Paul S; Wang X; Sasaki K; Thompson P; Burger J; Ferrajoli A; Estrov Z; O'Brien S; Keating M; Wierda WG; Jain N
Br J Haematol; 2021 Jul; 194(1):61-68. PubMed ID: 33973230
[TBL] [Abstract][Full Text] [Related]
16. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
[TBL] [Abstract][Full Text] [Related]
17. Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL).
Aldapt MB; Yassin M
Acta Biomed; 2021 May; 92(2):e2021192. PubMed ID: 33988158
[TBL] [Abstract][Full Text] [Related]
18. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Greil R; Tedeschi A; Moreno C; Anz B; Larratt L; Simkovic M; Gill D; Gribben JG; Flinn IW; Wang Z; Cheung LWK; Nguyen AN; Zhou C; Styles L; Demirkan F
Ann Hematol; 2021 Jul; 100(7):1733-1742. PubMed ID: 34018029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
